We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
MIRM Shares Rise 12% in a Week on Robust Preliminary 2024 Results
Read MoreHide Full Article
Shares of Mirum Pharmaceuticals (MIRM - Free Report) were up 12.1% this week, driven by investor enthusiasm after the company announced encouraging preliminary sales numbers for the fourth quarter and full year 2024, along with an encouraging outlook and growth strategy for 2025.
Mirum’s commercial portfolio comprises of lead product, Livmarli (maralixibat), which is approved for treating cholestatic pruritus in patients with Alagille syndrome worldwide. The drug is also approved for treating certain patients with progressive familial intrahepatic cholestasis in the United States and Europe.
MIRM acquired Travere Therapeutics’ bile acid products in August 2023, which added the latter’s Cholbam capsules and Chenodal tablets to its portfolio of commercialized drugs.
In the past year, shares of Mirum have rallied 73.3% against the industry’s decline of 16%.
Image Source: Zacks Investment Research
MIRM's Preliminary Results for 2024
The company reported preliminary net product sales of approximately $336 million in 2024, which surpassed the upper end of the guided range of $330-$335 million, provided with the third-quarter 2024 earnings release in November.
The company expects preliminary net product sales of Livmarli to be around $64 million in the fourth quarter and $213 million for full-year 2024.
Preliminary net product sales from Cholbam and Chenodal are expected to be around $35 million in the fourth quarter and $123 million for full-year 2024.
Cholbam is approved for treating bile acid synthesis disorders and Zellweger spectrum disorders.
Mirum’s cash, cash equivalents and investments were around $287 million as of Dec. 31, 2024. The company achieved positive cash flow from operations in the third quarter of 2024.
MIRM's 2025 Guidance & Business Goals
The company anticipates net product sales of around $420-$435 million for full-year 2025.
Mirum is evaluating Livmarli in the phase III EXPAND study for treating pruritus in rare cholestatic conditions. Enrollment in the study is expected to be completed in 2026.
Meanwhile, a new drug application seeking approval for Chenodiol for cerebrotendinous xanthomatosis (“CTX”) patients is currently under review in the United States. A decision from the FDA is now expected on March 28, 2025.
Chenodiol is not currently approved but has received a medical necessity medicine status from the FDA for treating CTX.
Mirum’s lead pipeline candidate, volixibat, is currently being evaluated in two phase IIb studies for treating patients with primary biliary cholangitis (the VANTAGE study) and primary sclerosing cholangitis (the VISTAS study).
Enrollment in the VISTAS study is expected to be completed in the second half of 2025 and top-line data from the same is anticipated in 2026. The company expects to complete enrollment in the VANTAGE study in 2026.
MIRM also plans to initiate a phase II study on its recently in-licensed PDE4D inhibitor, MRM-3379, for treating Fragile X syndrome later in 2025.
In the past 60 days, estimates for Voyager Therapeutics’ loss per share have narrowed from $1.72 to $1.48 for 2025. In the past year, shares of VYGR have plunged 29%.
VYGR’s earnings beat estimates in each of the trailing four quarters, the average surprise being 120.87%.
In the past 60 days, estimates for CytomX Therapeutics’ loss per share have narrowed from 46 cents to 35 cents for 2025. In the past year, shares of CTMX have increased 16.6%.
CTMX’s earnings beat estimates in two of the trailing four quarters while missing the same on the remaining two occasions, the average surprise being 115.70%.
In the past 60 days, estimates for Castle Biosciences’ loss per share have narrowed from $1.88 to $1.84 for 2025. In the past year, shares of CSTL have surged 29.9%.
CSTL’s earnings beat estimates in each of the trailing four quarters, the average surprise being 172.72%.
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
MIRM Shares Rise 12% in a Week on Robust Preliminary 2024 Results
Shares of Mirum Pharmaceuticals (MIRM - Free Report) were up 12.1% this week, driven by investor enthusiasm after the company announced encouraging preliminary sales numbers for the fourth quarter and full year 2024, along with an encouraging outlook and growth strategy for 2025.
Mirum’s commercial portfolio comprises of lead product, Livmarli (maralixibat), which is approved for treating cholestatic pruritus in patients with Alagille syndrome worldwide. The drug is also approved for treating certain patients with progressive familial intrahepatic cholestasis in the United States and Europe.
MIRM acquired Travere Therapeutics’ bile acid products in August 2023, which added the latter’s Cholbam capsules and Chenodal tablets to its portfolio of commercialized drugs.
In the past year, shares of Mirum have rallied 73.3% against the industry’s decline of 16%.
Image Source: Zacks Investment Research
MIRM's Preliminary Results for 2024
The company reported preliminary net product sales of approximately $336 million in 2024, which surpassed the upper end of the guided range of $330-$335 million, provided with the third-quarter 2024 earnings release in November.
The company expects preliminary net product sales of Livmarli to be around $64 million in the fourth quarter and $213 million for full-year 2024.
Preliminary net product sales from Cholbam and Chenodal are expected to be around $35 million in the fourth quarter and $123 million for full-year 2024.
Cholbam is approved for treating bile acid synthesis disorders and Zellweger spectrum disorders.
Mirum’s cash, cash equivalents and investments were around $287 million as of Dec. 31, 2024. The company achieved positive cash flow from operations in the third quarter of 2024.
MIRM's 2025 Guidance & Business Goals
The company anticipates net product sales of around $420-$435 million for full-year 2025.
Mirum is evaluating Livmarli in the phase III EXPAND study for treating pruritus in rare cholestatic conditions. Enrollment in the study is expected to be completed in 2026.
Meanwhile, a new drug application seeking approval for Chenodiol for cerebrotendinous xanthomatosis (“CTX”) patients is currently under review in the United States. A decision from the FDA is now expected on March 28, 2025.
Chenodiol is not currently approved but has received a medical necessity medicine status from the FDA for treating CTX.
Mirum’s lead pipeline candidate, volixibat, is currently being evaluated in two phase IIb studies for treating patients with primary biliary cholangitis (the VANTAGE study) and primary sclerosing cholangitis (the VISTAS study).
Enrollment in the VISTAS study is expected to be completed in the second half of 2025 and top-line data from the same is anticipated in 2026. The company expects to complete enrollment in the VANTAGE study in 2026.
MIRM also plans to initiate a phase II study on its recently in-licensed PDE4D inhibitor, MRM-3379, for treating Fragile X syndrome later in 2025.
Mirum Pharmaceuticals, Inc. Price
Mirum Pharmaceuticals, Inc. price | Mirum Pharmaceuticals, Inc. Quote
MIRM's Zacks Rank & Other Stocks to Consider
Mirum currently carries a Zacks Rank #2 (Buy).
Some other top-ranked stocks in the biotech sector are Voyager Therapeutics, Inc. (VYGR - Free Report) , CytomX Therapeutics, Inc. (CTMX - Free Report) and Castle Biosciences, Inc. (CSTL - Free Report) , each sporting a Zacks Rank #1 (Strong Buy) at present. You can see the complete list of today’s Zacks #1 Rank stocks here.
In the past 60 days, estimates for Voyager Therapeutics’ loss per share have narrowed from $1.72 to $1.48 for 2025. In the past year, shares of VYGR have plunged 29%.
VYGR’s earnings beat estimates in each of the trailing four quarters, the average surprise being 120.87%.
In the past 60 days, estimates for CytomX Therapeutics’ loss per share have narrowed from 46 cents to 35 cents for 2025. In the past year, shares of CTMX have increased 16.6%.
CTMX’s earnings beat estimates in two of the trailing four quarters while missing the same on the remaining two occasions, the average surprise being 115.70%.
In the past 60 days, estimates for Castle Biosciences’ loss per share have narrowed from $1.88 to $1.84 for 2025. In the past year, shares of CSTL have surged 29.9%.
CSTL’s earnings beat estimates in each of the trailing four quarters, the average surprise being 172.72%.